MCF Advisors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.47K Hold
25
﹤0.01% 1302
2026
Q1
$806 Buy
+25
New +$925 ﹤0.01% 1275
2025
Q3
Sell
-289
Closed -$7.81K 1006
2025
Q2
$7.81K Sell
289
-267
-48% -$7.73K ﹤0.01% 691
2025
Q1
$16.5K Sell
556
-108
-16% -$4.12K ﹤0.01% 578
2024
Q4
$26.3K Hold
664
﹤0.01% 500
2024
Q3
$22.6K Buy
664
+481
+263% +$13.5K ﹤0.01% 525
2024
Q2
$3.97K Hold
183
﹤0.01% 765
2024
Q1
$4.06K Buy
183
+91
+99% +$2.22K ﹤0.01% 744
2023
Q4
$2.53K Buy
+92
New +$2.22K ﹤0.01% 753

Other funds holding VCYT

MCF Advisors's VCYT Position: Q2 2026 in Review

MCF Advisors held its Veracyte (VCYT) position steady in Q2 2026 at 25 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #1302.

MCF Advisors first reported a position in VCYT in Q4 2023 and has held it in 9 quarters since. The position peaked at $26.3K in Q4 2024. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • MCF Advisors held 25 shares of Veracyte worth $1.47K as of Q2 2026.
  • MCF Advisors left its Veracyte share count unchanged in Q2 2026.
  • Veracyte made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1302 holding.
  • MCF Advisors first reported a position in Veracyte in Q4 2023 and has held it in 9 quarters since.
  • MCF Advisors's Veracyte position peaked at $26.3K in Q4 2024.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.